Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Comment by Actuarialon Feb 17, 2021 11:14am
125 Views
Post# 32584470

RE:RE:RE:CHECK out ONC.TO Cancer breakthrough?

RE:RE:RE:CHECK out ONC.TO Cancer breakthrough?upgrade to otcqx was mentioned before ...... it is no a surprise to me - not so excited. Naz is going to be the next Catalyst - within six weeks is my bet.
bringon10bagger wrote: What's interesting, Dan has eluded to moving up to the Naz and will happen but the question is when??? Maybe its already in motion.....he never mentioned moving to the otcqx .......Dan is becoming good at not sharing his poker hand.......Maybe next NR is the listing approval??

Goaweigh wrote: Interesting read on the science but the most relevant aspect of ONC to ATE is that it's listed on NAS and today it's done volume of close to 11,000,000 shares after receiving it's first buy recommendation from HC Wainright who has given it a target price of US $ 15.00

Now didn't we just see a rumour that maybe we may be listing NAS soon and possibly being sponsored by none other than HC Wainright !

Can you imagine what would happen if we did 11,000,000 volume !

Shitzki is all I can say.




askretka wrote:
Company has been working on a virus therapies to kill cancer for about 20 years. It may be all coming together. I never hijack boards like this but this may be a real breakthrough in cancer treatment. 15$ new target today. This might be just the beginning. I'm also an ATE Shareholders

 




<< Previous
Bullboard Posts
Next >>